As of 2026-04-13, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 56.19 mil USD. INO's TTM EBITDA according to its financial statements is -88.05 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 18.8x | 16.2x |
| Forward P/E multiples | 19.1x - 24.5x | 20.7x |
| Fair Price | (17.28) - (17.02) | (16.67) |
| Upside | -1729.9% - -1705.4% | -1673.0% |
| Date | EV/EBITDA |
| 2026-04-10 | -0.64 |
| 2026-04-09 | -0.63 |
| 2026-04-08 | -0.67 |
| 2026-04-07 | -0.63 |
| 2026-04-06 | -0.71 |
| 2026-04-02 | -0.71 |
| 2026-04-01 | -1.37 |
| 2026-03-31 | -1.37 |
| 2026-03-30 | -1.29 |
| 2026-03-27 | -1.23 |
| 2026-03-26 | -1.17 |
| 2026-03-25 | -1.15 |
| 2026-03-24 | -1.19 |
| 2026-03-23 | -1.23 |
| 2026-03-20 | -1.20 |
| 2026-03-19 | -1.27 |
| 2026-03-18 | -1.28 |
| 2026-03-17 | -1.31 |
| 2026-03-16 | -1.25 |
| 2026-03-13 | -1.28 |
| 2026-03-12 | -1.31 |
| 2026-03-11 | -1.32 |
| 2026-03-10 | -1.36 |
| 2026-03-09 | -1.36 |
| 2026-03-06 | -1.37 |
| 2026-03-05 | -1.31 |
| 2026-03-04 | -1.36 |
| 2026-03-03 | -1.31 |
| 2026-03-02 | -1.37 |
| 2026-02-27 | -1.45 |
| 2026-02-26 | -1.42 |
| 2026-02-25 | -1.49 |
| 2026-02-24 | -1.53 |
| 2026-02-23 | -1.45 |
| 2026-02-20 | -1.36 |
| 2026-02-19 | -1.35 |
| 2026-02-18 | -1.29 |
| 2026-02-17 | -1.25 |
| 2026-02-13 | -1.23 |
| 2026-02-12 | -1.20 |
| 2026-02-11 | -1.23 |
| 2026-02-10 | -1.32 |
| 2026-02-09 | -1.32 |
| 2026-02-06 | -1.28 |
| 2026-02-05 | -1.18 |
| 2026-02-04 | -1.29 |
| 2026-02-03 | -1.32 |
| 2026-02-02 | -1.33 |
| 2026-01-30 | -1.25 |
| 2026-01-29 | -1.23 |